**Business Performance:** Fabtech reported a solid FY26 with revenue from operations growing 25.7% YoY to ₹410.77 Cr.

Operational profit saw a 17.0% YoY increase to ₹36.60 Cr.

Despite a dip in reported Net Profit to ₹38.36 Cr from ₹46.45 Cr in FY25 due to exceptional items related to a TSA sale, the company maintains strong execution momentum. **Growth Drivers/Strategy:** The company is focused on expanding its platform through a European acquisition, forming joint ventures in key regions like KSA and East Africa, and strengthening working capital for aggressive growth.

A key strategic initiative includes taking on the Pre-Engineered Building (PEB) scope to gain end-to-end project control and larger ticket sizes. **Recent Developments:** Fabtech has entered the Animal Health segment with a vaccine project in Saudi Arabia and secured large-scale pharma and infrastructure wins in Africa.

They are also expanding into premium, high-margin markets. **Key Financial Metrics:** FY26 Revenue from Operations: ₹410.77 Cr (↑ 25.7% YoY). Order Book: ₹900+ Cr, providing strong revenue visibility. **Management Commentary/Outlook:** Fabtech anticipates a wider runway ahead, underpinned by a robust enquiry pipeline.

The company aims to expand its PAT margin from 8-9% to 11-13% through localization, alternative sourcing, and PEB execution.

They project FY27 standalone revenue of ₹500 Cr and PAT of ₹45 Cr.

The vision is to climb the value curve towards advanced-technology life-sciences builds by 2030, capitalizing on a 15-year structural opportunity in regional medicinal sovereignty.